Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Patent
1995-01-26
1996-10-15
Berch, Mark L.
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
C07D47334, A61K 3152
Patent
active
055655661
ABSTRACT:
Novel compounds and a method of using them to antagonize adenosine receptors are provided wherein the compounds are selected from the group of racemic mixtures or optically active compounds represented by the general formula: ##STR1## wherein R.sub.2 is selected from the group consisting of cycloalkyl radicals having from 3 to 8, preferably 3 to 7, ring carbon atoms, alkyl radicals having from 1 to 10, carbon atoms, aralkyl radicals having from 7 to 14, preferably 7 to 10, carbon atoms, and heteroatom- and halogen-substituted derivatives thereof wherein said heteroatom may be selected from the group consisting of nitrogen, phosphorus, sulfur and oxygen; R.sub.1 may be hydrogen or R.sub.2, and R.sub.3 is selected from the group consisting of hydrogen, halogen, amine, carboxy, thio, sufonate, sulfonamide, sulfone, sulfoxamide, phenyl, alkyl-substituted amine, cycloalkyl-substituted amine, alkyl radicals having from 1 to 10 carbon atoms, and cycloalkyl radicals having from 3 to 8, preferably 5 to 6, ring carbon atoms. R.sub.4 is selected from the group consisting of benzyl, phenyl, and alkyl groups comprising from 1 to 4 carbon atoms, wherein said alkyl group can be substituted with oxygen, for example ethers and alcohols. R.sub.5 is selected from the group consisting of hydrogen; hydroxy; sulfonate; halogen; alkoxy and cycloalkoxy groups comprising 1 to 6 carbon atoms, wherein said alkoxy and cycloalkoxy groups can be substituted with phenyl; and amine, wherein said amine can be substituted with alkyl, cycloalkyl, or phenyl. Optically active compounds are especially active as antagonists of A.sub.1 adenosine receptors.
REFERENCES:
patent: 2881164 (1959-04-01), Kissman et al.
patent: 3502649 (1970-03-01), Thiel et al.
patent: 3509129 (1970-04-01), Kampe et al.
patent: 3796700 (1974-03-01), Yoshioka et al.
patent: 3851056 (1974-11-01), Stork et al.
patent: 3901876 (1975-08-01), Vorbr uggen et al.
patent: 3929763 (1975-12-01), Fauland et al.
patent: 3930005 (1975-12-01), Wojnar et al.
patent: 3989833 (1976-11-01), Jonas et al.
patent: 4029884 (1977-06-01), Stein et al.
patent: 4081534 (1978-03-01), Elion et al.
patent: 4090021 (1978-05-01), Vorbruggen
patent: 4167565 (1978-09-01), Stein et al.
patent: 4189485 (1980-02-01), Matsuno et al.
patent: 4199574 (1980-04-01), Schaeffer
patent: 4224438 (1980-09-01), Fauland et al.
patent: 4287188 (1981-09-01), Schaeffer
patent: 4294831 (1981-10-01), Schaeffer
patent: 4364922 (1982-12-01), Berne et al.
patent: 4440777 (1984-04-01), Zupan
patent: 4495180 (1985-01-01), Alexander
patent: 4514405 (1985-04-01), Irmscher et al.
patent: 4612315 (1986-09-01), Jacobson et al.
patent: 4696932 (1987-09-01), Jacobson et al.
patent: 4714697 (1987-12-01), Trivedi
patent: 4751292 (1988-06-01), Fox
patent: 4783530 (1988-11-01), Rzeszotarski et al.
patent: 4798833 (1989-01-01), Johansson et al.
patent: 4853386 (1989-08-01), Friebe et al.
patent: 4980379 (1990-12-01), Belardinelli et al.
patent: 5066655 (1991-11-01), Olsson
patent: 5117830 (1992-06-01), McAfee
patent: 5256398 (1993-10-01), McAfee
"New Ways to Scan the Myocardium," The Medical Letter 33:87-90 (1991).
Bertolet et al., "Attenuation of Adenosine-Induced Chest Pain with N-0861 (N.sup.6 -Endonorbornan-2-yl-9-methyladenine), A Selective A.sub.1 Adenosine Receptor Antagonist," 5th Amer. Coll. of Cardiol., 43rd Annual Sci. Session (Mar. 1994).
Jacobson et al., "Adenosine Receptors: Pharmacology, Structure-Activity Relationships, and Therapeutic Potential," J. Med. Chem. 35(3):407-422 (1992).
McNulty, S. A., "Pharmacological Interventional Testing for Myocardial Perfusion: A New Application for Adenosine," Cardiovascular Nursing 28(4):24-28 (1992).
Rose et al., "Safety, Tolerability, Renal Effects and Pharmacokinetics in Man of Single Doses of FK453, A Novel Adenosine A.sub.1 Receptor Antagonist," Presented at the British Pharmacological Society Meeting, Abstract P149 (1991).
Stiles, G. L., "Adenosine Receptors: Structure, Function and Regulation," TIPS Reviews:486-490 (Dec. 1986).
Terai et al., "The renal effects of FR-113453, a potent non-xanthine adenosine antagonist," XIth Intl. Cong. of Pharmacol., Amsterdam, The Netherlands, Abstract No. P.tu.435 (Jul. 2-6, 1990).
Translation of JP-58-167599.
Translation of JP-58 167800.
Anzai and Matsui, "Compounds relating to dibenzoyladenine riboside. Choice between the N.sup.6,1-dibenzoyl and N.sup.6,N.sup.6 -dibenzoyl structures," Chem. Abstracts 80(3):454 Abstract No. 15146c (1974).
Baer and Muller, "Adenosine receptors in smooth muscle," in: Regulatory Function of Adenosine, Berne et al., eds., Boston, p. 500 (1983).
Bruns, R. F., "Adenosine Antagonism by Purines, Pteridines and Benzopteridines in Human Fibroblasts," Biochem. Pharmacol. 30:325-333 (1981).
Bruns et al., "Characterization of the A.sub.2 Adenosine Receptor Labeled by [.sup.3 H]NECA in Rat Striatal Membranes," Molec. Pharmacol. 29:331-346 (1986).
Burnstock et al., "Evidence that the P.sub.1 -purinoceptor in the guinea pig taenia coli is an A.sub.2 -subtype," Br. J. Pharmacol. 81:533-541 (1984).
Carstens and Goldner, "6,9-Disubstituted purine derivatives," Chem. Abstracts 56(9):Abstract No. 10167i-10168d (1962).
Collis, M. G., "Evidence for an A.sub.1 -adenosine receptor in the guinea pig atrium," Br. J. Pharmacol. 78:207-212 (1983).
Daly, J. W., "Adenosine Receptors," Advances in Cyclic Nucleotide and Protein Phosphorylation Research 19:29-46 (1985).
Daly, J. W., "Adenosine Receptors: Targets for Future Drugs," J. Med. Chem. 25(3):197-207 (1982).
Daly et al., "Non-xanthine heterocycles: activity as antagonists of A.sub.1 - and A.sub.2 -adenosine receptors," Chem. Abstracts 108(21):Abstract No. 179589x (1988).
Daly et al., "Structure-Activity Relationship for N.sup.6 -Substituted Adenosines at a Brain A.sub.1 -Adenosine Receptor with a Comparison to an A.sub.2 -Adenosine Receptor Regulating Coronary Blood Flow," Biochem. Pharmacol. 35(15):2467-2481 (1986).
Davies et al., "Pyrazolo [3,4-d]pyrimidines as Adenosine Antagonists," Life Sci. 34:2117-2128 (1984).
Elliot et al., "Structural analogs in the study of cytokinin action," Chem. Abstracts 79:98 Abstract No. 8824lu (1973).
Fox and Kurpis, "Binding Characteristics of an Adenosine Receptor in Human Placenta," J. Biol. Chem. 258(11):6952-6955 (1983).
Fox et al., "Effect of substituents at the 9-position on cytokinin activity," Chem. Abstracts 79(19):78 Abstract No. 112299s (1973).
Fujii et al., "Hydrolytic Deamination versus Dimroth Rearrangement in the 9-Substituted Adenine Ring: Effect of an .omega.-Hydroxyalkyl Group at the 1-Position," Chem. Pharm. Bull. 34(3):1094-1107 (1986).
Geiger and Glavin, "Adenosine Receptor Activation in Brain Reduces Stress-Induced Ulcer Formation," Eur. J. Pharmacol. 115:185-190 (1985).
Glennon et al., "Mesoionic Xanthine Analogues: Antagonists of Adenosine Receptors," J. Med. Chem. 27:1364-1367 (1984).
Goldner and Carstens, "Synthesis of 9-substituted purine derivatives. I. 2,9-, 2,6,9- and 6,9-substituted purines," Chem. Abstracts 56(1):470 Abstract No. 470c-471e (1962).
Griffith et al., "8-phenyltheophylline: a potent P.sub.1 purinoreceptor antagonist," Eur. J. Pharmacol. 75:61-64 (1981).
Hashizume et al., "Synthesis and biological activity of some new 6-benzylamino-9-alkylpurines," Chem. Abstracts 87(25):202 Abstract No. 195316j (1977).
Hill et al., "Attenuation of Adenosine A.sub.1 Receptor Mediated Effects by N-0861, (N.sup.6 -Endonorboran-2-yl-9-Methyladenine) In Humans," Drug Devel. Res. 31(4):278 Abstract No. 1185 Presented at the 5th Intl. Symp. on Adenosine and Adenosine Nucleotides, Philadelphia, PA, (May 9-13, 1994).
Itaya et al., "Rate Study and Mechanism of the Dimroth Rearrangement of 1-alkoxy-9-alkyladenines and 1-alkyl-9-methyladenines," Tetrahedron 28:535-547 (1972).
Itaya et al., "Syntheses of N,N,3- and N,N,9-trialkyladenines by alkylation of N,N-dialkyladenines," Chem. Abstracts 93(15):716 Abstract No. 150216j (1980).
Jacobson et al., "[.sup.3 H]Xanthine amine congener of 1,3-dipropyl-8-phenylxanthine: An antagonist radioligand for adenosine receptors," Proc. Natl. Acad. Sci. USA 83:4089-4093
Berch Mark L.
Discovery Therapeutics Inc.
LandOfFree
N.sup.6 -substituted 9-methyladenines: a new class of adenosine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N.sup.6 -substituted 9-methyladenines: a new class of adenosine , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N.sup.6 -substituted 9-methyladenines: a new class of adenosine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1247429